Daijiworld Media Network - Jaipur
Jaipur, Apr 22: The Commissionerate of Food Safety and Drug Control, Rajasthan has issued a public alert after laboratory testing identified seven pharmaceutical products as “Not of Standard Quality,” triggering a statewide recall and enforcement action.
The tests, conducted between April 1 and April 15, 2026, found multiple batches of medicines failing to meet required safety and efficacy standards. Acting on the findings, the Drug Controller has directed all district drug control officers to immediately remove the affected batches from circulation under provisions of the Drugs and Cosmetics Act, 1940.
Commissioner Dr. T. Shubhamangala said routine inspections and quality surveillance are carried out to ensure only safe and effective medicines reach patients. She noted that the latest testing cycle revealed serious deviations in composition and performance across several drugs, raising concerns about their therapeutic reliability.
Among the flagged products is Cefixime oral suspension (LORAXIM Dry Syrup), which failed assay standards due to incorrect active ingredient levels. Albendazole tablets were found to be non-compliant in dissolution testing, indicating improper release of the drug in the body.
Other medicines on the list include combinations used for respiratory conditions, such as Ambroxol, Levosalbutamol, and Guaiphenesin drops, which failed assay requirements, as well as Methylprednisolone tablets, which showed multiple quality failures in both assay and dissolution tests.
Cough syrup formulations and antibiotics were also affected. Dextromethorphan-based syrup showed reduced chlorpheniramine content, while antibiotics such as Cefuroxime Axetil tablets and Ciprofloxacin tablets failed key quality parameters, including assay and dissolution benchmarks.
Ajay Phatak, Drug Controller of Rajasthan, confirmed that instructions have been issued to all hospitals, pharmacies, and distributors—both government and private—to immediately halt the sale and use of the affected batches.
He also ordered enhanced scrutiny of other batches manufactured by the same companies to prevent further public health risks.
Authorities warned that any violation of the recall order will invite strict legal action under drug safety regulations, as the state intensifies efforts to ensure pharmaceutical quality and patient safety.